Tumor Biology

, Volume 37, Issue 1, pp 723–727 | Cite as

RETRACTED ARTICLE: Survivin mRNA-circulating tumor cells are associated with prostate cancer metastasis

  • Huansheng Wang
  • Mingshan Yang
  • Jian Xu
  • Benkui Zou
  • Qian Zhou
  • Jiasheng Bian
  • Xingwu Wang
Original Article


Detection of circulating tumor cells (CTCs) has been made to develop reliable assays for early diagnosis of various cancers. Overexpression of survivin in cancer cells is strongly associated with tumor progression. Although upregulation of survivin is observed in various tumors, its expression profile in the peripheral blood of prostate cancer (PCa) patients has not yet been investigated. In this study, we validated the application of survivin as the tumor marker to detect CTC and assessed its utility for diagnosis of PCa distant metastasis. Immunohistochemistry and quantitative real-time PCR (QRT-PCR) were performed to confirm the levels of surviving expression in PCa tissues. In addition, CTC values in 3 mL of peripheral blood from PCa patients, benign prostate hyperplasia (BPH) patients, and normal controls were also measured by the survivin-targeted PCR. Our results showed that surviving was overexpressed in PCa tissues. The median levels of blood surviving mRNA of PCa patients, BPH patients, and normal controls were 5.67 (range from 0 to 12.46), 2.24 (range from 0 to 6.55), and 1.85 (range from 0 to 3.82), respectively. The levels of survivin are positively associated with PCa distant metastasis. Our results concluded that quantitation of CTCs through survivin-PCR could be a promising marker for diagnosis of PCa metastasis.


Prostate cancer Circulating tumor cell Survivin mRNA Metastasis 



This paper was supported by the National Key Basic Research Development Plan (973 Plan) (2011CB504302).

Conflicts of interest



  1. 1.
    Siegel R, Ma J, Zou Z, Jemal A. Cancer statistics. CA Cancer J Clin. 2014;64:9–29.CrossRefPubMedGoogle Scholar
  2. 2.
    Zhu Y, Yang XQ, Han CT, Dai B, Zhang HL, Shi GH, et al. Pathological features of localized prostate cancer in China: a contemporary analysis of radical prostatectomy specimens. PLoS One. 2015;10(3), e0121076.CrossRefPubMedPubMedCentralGoogle Scholar
  3. 3.
    Metwalli AR, Rosner IL, Cullen J, Chen Y, Brand T, Brassell SA, et al. Elevated alkaline phosphatase velocity strongly predicts overall survival and the risk of bone metastases in castrate-resistant prostate cancer. Urol Oncol. 2014;32(6):761–8.CrossRefPubMedPubMedCentralGoogle Scholar
  4. 4.
    Bastian PJ et al. Prognostic value of preoperative serum cell-free circulating DNA in men with prostate cancer undergoing radical prostatectomy. Clin Cancer Res. 2007;13:5361–7.CrossRefPubMedGoogle Scholar
  5. 5.
    Danila DC et al. Circulating tumor cell number and prognosis in progressive castration-resistant prostate cancer. Clin Cancer Res. 2007;13:7053–8.CrossRefPubMedGoogle Scholar
  6. 6.
    Lucci A, Hall CS, Lodhi AK, Bhattacharyya A, Anderson AE, Xiao L, et al. Circulating tumour cells in non-metastatic breast cancer: a prospective study. Lancet Oncol. 2012;13:688–95.CrossRefPubMedGoogle Scholar
  7. 7.
    Cohen SJ, Punt CJ, Iannotti N, Saidman BH, Sabbath KD, Gabrail NY, et al. Prognostic significance of circulating tumor cells in patients with metastatic colorectal cancer. Ann Oncol. 2009;20:1223–9.CrossRefPubMedGoogle Scholar
  8. 8.
    Punnoose EA, Alwal S, Liu W, et al. Evaluation of circulating tumor cells and circulating tumor DNA in non-small cell lung cancer: association with clinical endpoints in a phase II clinical trial of pertuzumab and erlotinib. Clin Cancer Res. 2012;18:2391–401.CrossRefPubMedGoogle Scholar
  9. 9.
    Altieri DC. Survivin, versatile modulation of cell division and apoptosis in cancer. Oncogene. 2003;22:8581–9.CrossRefPubMedGoogle Scholar
  10. 10.
    Altieri DC. Validating survivin as a cancer therapeutic target. Nat Rev Cancer. 2003;4:46–54.CrossRefGoogle Scholar
  11. 11.
    Yie S-M, Luo B, Ye N-Y, et al. Detection of survivin-expressing circulating cancer cells in the peripheral blood of breast cancer patients by a RT-PCR ELISA. Clin Exp Metastasis. 2006;23:279–89.CrossRefPubMedGoogle Scholar
  12. 12.
    Cao M, Yie S-M, Mu S-M, et al. Detection of survivin-expressing circulating cancer cells in the peripheral blood of patients with esophageal squamous cell carcinoma and its clinical significance. Clin Exp Metastasis. 2009;26:751–8.CrossRefPubMedGoogle Scholar
  13. 13.
    Yie S-M, Lou B, Ye S-R, et al. Clinical significance of detecting survivin-expressing circulating cancer cells in patients with non-small cell lung cancer. Lung Cancer. 2009;63:284–90.CrossRefPubMedGoogle Scholar
  14. 14.
    Yie S-M, Lou B, Ye S-R, et al. Detection of survivin-expressing circulating cancer cells (CCCs) in peripheral blood of patients with gastric and colorectal cancer reveals high risks of relapse. Ann Surg Oncol. 2008;15:3073–82.CrossRefPubMedGoogle Scholar
  15. 15.
    Tang X-P, Li J, Yu L-C, et al. Clinical significance of surviving and VEGF mRNA detection in the cell fraction of the peripheral blood in non-small cell lung cancer patients before and after surgery. Lung Cancer. 2013;81:273–9.CrossRefPubMedGoogle Scholar
  16. 16.
    Livak KJ, Schimittgen TD. Analysis of reactive gene expression data using real-time quantitative PCR and 2−ΔΔCt method. Method. 2001;25:402–8.CrossRefGoogle Scholar
  17. 17.
    Lou J, Ben S, Yang G, Liang X, Wang X, Ni S, et al. Quantification of rare circulating tumor cells in non-small cell lung cancer by ligand-targeted PCR. PLoS One. 2013;8(12), e80458.CrossRefPubMedPubMedCentralGoogle Scholar
  18. 18.
    Jin J-K, Dayyani F, Gallick GE. Steps in prostate cancer progression that lead to bone metastasis. Int J Cancer. 2011;128:2545–61.CrossRefPubMedPubMedCentralGoogle Scholar
  19. 19.
    Palmer TD, Ashby WJ, Lewis JD, Zijlstra A. Targeting tumor cell motility to prevent metastasis. Adv Drug Deliv Rev. 2011;63:568–81.CrossRefPubMedPubMedCentralGoogle Scholar
  20. 20.
    Heidenreich A, Bellmunt J, Bolla M, Joniau S, Mason M, et al. EAU guidelines on prostate cancer. Part 1: screening, diagnosis, and treatment of clinically localized disease. Eur Urol. 2011;59(1):61–71.CrossRefPubMedGoogle Scholar

Copyright information

© International Society of Oncology and BioMarkers (ISOBM) 2015

Authors and Affiliations

  • Huansheng Wang
    • 1
  • Mingshan Yang
    • 1
  • Jian Xu
    • 1
  • Benkui Zou
    • 1
  • Qian Zhou
    • 1
  • Jiasheng Bian
    • 1
  • Xingwu Wang
    • 2
  1. 1.Department of Urology SurgeryShandong Cancer HospitalJinanChina
  2. 2.Department of Central LaboratoryShandong Cancer HospitalJinanChina

Personalised recommendations